PRESS RELEASE 2022

Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

By celia in PRESS RELEASE 2022 on 16 December 2022

Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle...

Ferring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A novel first-in-class microbiota-based live biotherapeutic

By celia in PRESS RELEASE 2022 on 30 November 2022

Ferring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A...

Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD)

By celia in PRESS RELEASE 2022 on 15 November 2022

…

Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs

By celia in PRESS RELEASE 2022 on 07 November 2022

Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in...

Ferring Pharmaceuticals and Blackstone Life Sciences restructure novel gene therapy collaboration

By celia in PRESS RELEASE 2022 on 17 October 2022

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) voted...

Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660

By celia in PRESS RELEASE 2022 on 22 September 2022

Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic

By celia in PRESS RELEASE 2022 on 09 August 2022

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) will hold a meeting on September 22, 2022...

Ferring announces ground-breaking and inclusive family building benefits package for all its employees globally

By celia in PRESS RELEASE 2022 on 14 July 2022

Ferring Pharmaceuticals is committed to building families of every shape and size. As part of this commitment, Ferring has announced the introduction of a new global family building benefits package for its employees...

Ferring Announces New Collaboration for Development of Olamkicept

By celia in PRESS RELEASE 2022 on 09 June 2022

Ferring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions...

Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic

By celia in PRESS RELEASE 2022 on 24 May 2022

New subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660.